Viking Therapeutics Inc Stock

Viking Therapeutics (NASDAQ: VKTX) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries

Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX)

Investing in biotechnology requires a balance between groundbreaking scientific innovation and the realities of clinical development. Choosing between CRISPR Therapeutics (NASDAQ:CRSP) and Viking

The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 billion market cap company will be bought

Viking Therapeutics (NASDAQ: VKTX) is a challenger in the obesity drugs gold rush, trailing Eli Lilly and Novo Nordisk as they rake in cash from their highly successful medicines. Viking's lead

Viking Therapeutics (NASDAQ: VKTX) is one of the hopefuls in a very exciting pharmaceutical and biotech space right now: the weight loss drug market. Today, pharma giants Eli Lilly and Novo Nordisk

Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in June, according to data from S&P Global Market Intelligence. The move comes as optimism rises over the company's pipeline development

Shares of Viking Therapeutics (NASDAQ: VKTX) have climbed by 27% over the past month. The drugmaker is a serious candidate to make waves in the large and growing anti-obesity drug market. With

High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the

GLP-1 drugs are proving helpful for many conditions, not just weight loss. In studies, they have shown they can reduce cardiovascular risk, sleep apnea, and even curb addictions. They have the

Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have moved in exactly the wrong direction this year, down 8% to date. However, the drugmaker has important catalysts on the

The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) split it through their GLP-1 medicines: Zepbound

When investing, it's easy to be impressed with stocks that deliver almost overnight gains. We might see this after an initial public offering -- for example, artificial intelligence (AI) chip

Viking Therapeutics (NASDAQ: VKTX) has seen its stock stumble in recent times -- for example, it's slipped over the past year. But over five years, shares of the biotech company have climbed more

An analyst at the banking giant Truist Financial has an $83 price target on Viking Therapeutics (NASDAQ: VKTX), which is particularly notable given that Viking opened at $28.75 per share on June 8

Despite being one of the NFL's most winningest franchises, the Minnesota Vikings have never won a Super Bowl. Viking Holdings (NYSE: VIK), on the other hand, is winning it all in its market. Shares

The debate over Viking Therapeutics (NASDAQ: VKTX) will take another turn in Q3. As ever, you have to factor in what competitors such as Eli Lilly and Novo Nordisk are doing, as well as the unique

The key to understanding the investment case for Viking Therapeutics (NASDAQ: VKTX) stock lies in the benefits of having a weight-loss drug, namely VK2735, in development in both subcutaneous